GLP-1 Receptor Agonists for Diabetes: Evidence and Outcomes

View Evidence Brief

Evidence on outcomes studied for GLP-1 Receptor Agonists

Evidence related to GLP-1 receptor agonist therapies in diabetes studies.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

100

Evidence Pairs

Moderate Evidence

Evidence Strength: 66/100

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

GLP-1 Receptor Agonists evidence appears to center on HbA1c.

Among 58 indexed studies and 6 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

HbA1c appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 18 evidence pairs - 40 studies

Why this appears here

Strong evidenceConsistent resultsPositive effect signalMultiple RCTs

HbA1c

29 studies

EvidenceScore™

86/100

ConsistencyScore™

86/100

Body weight

28 studies

EvidenceScore™

86/100

ConsistencyScore™

88/100

Evidence Snapshot

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Strong positive signal

HbA1c

Across 11 studies, Semaglutide shows a consistent strong positive signal for HbA1c.

11 studies

EvidenceScore™: 85.53846153846153/100

View supporting studies

Moderate positive signal

Body weight

Across 9 studies, Semaglutide shows a consistent moderate positive signal for Body weight.

9 studies

EvidenceScore™: 85.45299145299145/100

View supporting studies

Strong positive signal

HbA1c

Across 13 studies, Tirzepatide shows a consistent strong positive signal for HbA1c.

13 studies

EvidenceScore™: 83.35502958579882/100

View supporting studies

Strong positive signal

Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 7 studies, Semaglutide shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

7 studies

EvidenceScore™: 83.20879120879121/100

View supporting studies

Evidence signal

All-cause mortality

Across 6 studies, Semaglutide shows a evidence signal for All-cause mortality.

6 studies

EvidenceScore™: 82.94871794871796/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

HbA1c is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

HbA1c

Body weight

HbA1c

29 studies

EvidenceScore™

86/100

ConsistencyScore™

86/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present

Evidence basis: 19 evidence pairs - 46 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Cardiovascular events may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Cardiovascular events

Basal insulin dose

Cardiovascular events

3 studies

EvidenceScore™

79/100

ConsistencyScore™

100/100

Why this appears here

Positive effect signalLimited study volume

Evidence basis: 5 evidence pairs - 10 studies

View supporting studies

Question Highlights

Quick answers to the most important questions supported by the available evidence.

Explore all evidence questions

What outcomes has GLP-1 Receptor Agonists been studied for?

HbA1c, Body weight, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) are among the most studied areas in relation to GLP-1 Receptor Agonists.

HbA1c, Body weight, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) are among the best-supported options in the available evidence across 58 studies.

Consistency cannot yet be determined.

View full answer

Does GLP-1 Receptor Agonists improve HbA1c?

GLP-1 Receptor Agonists appears to improve HbA1c.

Strong evidence is based on 29 supporting studies.

Population details are unavailable.

View full answer

How does GLP-1 Receptor Agonists compare across studied outcomes?

HbA1c, Body weight, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) have available evidence for GLP-1 Receptor Agonists, but the comparison requires review of the underlying studies.

Evidence is available for both Body weight and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization); the underlying studies are needed for a direct comparison.

Population details are unavailable.

View full answer

Explore all evidence questions

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

What outcomes has GLP-1 Receptor Agonists been studied for?

outcomes studied

Emerging Evidence

HbA1c, Body weight, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) are among the most studied areas in relation to GLP-1 Receptor Agonists.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 29 studies
2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 28 studies
3
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 7 studies

Why this answer: This answer is based on 58 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

Does GLP-1 Receptor Agonists improve HbA1c?

intervention outcome_effect

Strong Evidence

GLP-1 Receptor Agonists appears to improve HbA1c.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 29 studies

Why this answer: This answer is based on 29 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Does GLP-1 Receptor Agonists affect body weight?

intervention outcome_effect

Strong Evidence

GLP-1 Receptor Agonists may improve Body weight.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 28 studies

Why this answer: This answer is based on 28 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Which outcomes have the strongest evidence for GLP-1 Receptor Agonists?

evidence strength

Strong Evidence

HbA1c, Body weight, and Composite cardiovascular events (CV death, MI, stroke, HF hospitalization) have the strongest available evidence signals for GLP-1 Receptor Agonists.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 29 studies
2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 28 studies
3
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 7 studies

Why this answer: This answer is based on 46 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Where does GLP-1 Receptor Agonists need more research?

research gaps

Moderate Evidence

Incidence of myocardial infarction, Proportion achieving HbA1c <7.0%, and Basal insulin dose need more research in relation to GLP-1 Receptor Agonists.

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
Basal insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 2 studies
2
Incidence of myocardial infarction
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 2 studies
3
Proportion achieving HbA1c <7.0%
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 2 studies

Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

How does GLP-1 Receptor Agonists compare across studied outcomes?

cross outcome_comparison

Strong Evidence

ConsistencyScore™: Results are consistent across studies.

Ranked evidence signals

1
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 85.5 | strong positive | ConsistencyScore™ Consistent | 29 studies
2
Body weight
EvidenceScore™ Strong | EvidenceScore™ 85.5 | moderate positive | ConsistencyScore™ Consistent | 28 studies
3
Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 7 studies

Why this answer: This answer is based on 46 supporting studies with consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Evidence summary for AI and search

Among 58 indexed studies and 6 interventions, the strongest signals are summarized from the available evidence. HbA1c appears to be one of the clearer current evidence signals.